IL213473A - Crystalline forms of genistein sodium salt dihydrate, compositions comprising the same and uses thereof - Google Patents

Crystalline forms of genistein sodium salt dihydrate, compositions comprising the same and uses thereof

Info

Publication number
IL213473A
IL213473A IL213473A IL21347311A IL213473A IL 213473 A IL213473 A IL 213473A IL 213473 A IL213473 A IL 213473A IL 21347311 A IL21347311 A IL 21347311A IL 213473 A IL213473 A IL 213473A
Authority
IL
Israel
Prior art keywords
genistein
crystalline
sodium salt
salt
salt dihydrate
Prior art date
Application number
IL213473A
Other languages
English (en)
Hebrew (he)
Other versions
IL213473A0 (en
Original Assignee
Axcentua Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcentua Pharmaceuticals Ab filed Critical Axcentua Pharmaceuticals Ab
Publication of IL213473A0 publication Critical patent/IL213473A0/en
Publication of IL213473A publication Critical patent/IL213473A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
IL213473A 2008-12-11 2011-06-09 Crystalline forms of genistein sodium salt dihydrate, compositions comprising the same and uses thereof IL213473A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12177808P 2008-12-11 2008-12-11
US12178708P 2008-12-11 2008-12-11
PCT/US2009/067664 WO2010068861A1 (en) 2008-12-11 2009-12-11 Crystalline forms of genistein

Publications (2)

Publication Number Publication Date
IL213473A0 IL213473A0 (en) 2011-07-31
IL213473A true IL213473A (en) 2014-12-31

Family

ID=42243089

Family Applications (2)

Application Number Title Priority Date Filing Date
IL213473A IL213473A (en) 2008-12-11 2011-06-09 Crystalline forms of genistein sodium salt dihydrate, compositions comprising the same and uses thereof
IL235943A IL235943A0 (en) 2008-12-11 2014-11-27 Genistein salts, their crystalline forms, preparations containing them and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL235943A IL235943A0 (en) 2008-12-11 2014-11-27 Genistein salts, their crystalline forms, preparations containing them and their uses

Country Status (11)

Country Link
US (2) US9012495B2 (OSRAM)
EP (1) EP2373326B1 (OSRAM)
JP (3) JP5898958B2 (OSRAM)
KR (2) KR101849059B1 (OSRAM)
CN (2) CN102292097B (OSRAM)
AU (1) AU2009324489B2 (OSRAM)
BR (1) BRPI0923504A2 (OSRAM)
CA (1) CA2746652C (OSRAM)
IL (2) IL213473A (OSRAM)
WO (1) WO2010068861A1 (OSRAM)
ZA (1) ZA201105045B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102292097B (zh) 2008-12-11 2015-05-27 艾克赛特药品有限公司 染料木黄酮的晶型
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
WO2011104667A1 (en) * 2010-02-25 2011-09-01 Anthem Biosciences Private Limited Basic aminoacid salts of polyphenols
CN102442989B (zh) * 2010-10-12 2015-04-08 上海睿智化学研究有限公司 一种金雀异黄素盐、其晶体及其制备方法
CN102442990B (zh) * 2010-10-12 2015-03-11 上海睿智化学研究有限公司 一种金雀异黄素烟酰胺共晶、其晶体及其制备方法
CN102442991B (zh) * 2010-10-12 2015-03-11 上海睿智化学研究有限公司 一种金雀异黄素维生素b6共晶、其晶体及其制备方法
CN105963246B (zh) * 2016-05-06 2018-12-25 荆楚理工学院 一种染料木素盐口服溶液剂及制备方法和应用
CN105853350A (zh) * 2016-05-24 2016-08-17 荆楚理工学院 一种染料木素溶液及制备方法和应用
CN109666014A (zh) * 2018-12-12 2019-04-23 荆门医药工业技术研究院 一种染料木素衍生物盐的制备方法及其应用
EP4255415A1 (en) 2020-12-03 2023-10-11 Delta 4 GmbH Genistein for use in the treatment of focal segmental glomerulosclerosis (fsgs)
AU2023261942A1 (en) 2022-04-28 2024-09-19 GreenStone Biosciences, Inc. Treatment of the adverse cardiovascular effects of cannabinoids
WO2025117337A1 (en) 2023-11-28 2025-06-05 GreenStone Biosciences, Inc. Genistein phosphate derivatives

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
EP1477178A3 (en) 1992-05-19 2005-02-16 KELLY, Graham Edmund Health supplements containing phyto-oestrogens, analogues or metabolites thereof
DE4331233A1 (de) * 1993-09-15 1995-03-16 Basf Ag Verfahren zur Herstellung von Hydroxyoxaalkylmelaminen
US5569459A (en) * 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5554519A (en) 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
PL179170B1 (pl) * 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9613455D0 (en) 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US5981775A (en) 1998-09-16 1999-11-09 Board Of Trustees Operating Michigan State University Process for the preparation of isoflavones
US6194469B1 (en) * 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AUPQ520300A0 (en) * 2000-01-21 2000-02-17 Novogen Research Pty Ltd Food product and process
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
ES2219259T3 (es) 2000-06-16 2004-12-01 Linnea S.A. Complejo soluble en agua de un extracto de ginkgo biloba, procedimiento para su preparacion y composicion que lo comprende.
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
US6541613B2 (en) * 2000-12-15 2003-04-01 Uyrex Corporation Isoflavone derivatives
PL205635B1 (pl) * 2001-04-09 2010-05-31 Inst Farmaceutyczny Nowe pochodne genisteiny i zawierające je środki farmaceutyczne
CN100348592C (zh) * 2001-12-28 2007-11-14 中国人民解放军第二军医大学 3，7，8－三取代－5－羟基苯并－γ－吡喃酮类化合物及其制备方法
US20040023981A1 (en) 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
MY136174A (en) 2002-12-24 2008-08-29 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
EP1765379A4 (en) * 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
ES2353001T3 (es) * 2004-07-20 2011-02-24 Furfural Español, S.A. Uso de compuestos derivados de la 2,3-dehidronaringenina para el tratamiento de procesos inflamatorios y composición farmacéutica que contiene dichos derivados.
ES2351257T3 (es) 2005-02-15 2011-02-02 Dsm Ip Assets B.V. Composiciones que contienen polisacáridos.
WO2007000193A1 (en) * 2005-06-29 2007-01-04 Dsm Ip Assets B.V. Isoflavone nanoparticles and use thereof
US20070037875A1 (en) 2005-08-11 2007-02-15 The Scripps Research Institute Genistein inhibition of transthyretin amyloidosis
WO2007061254A1 (en) 2005-11-25 2007-05-31 B & C Biopharm. Co., Ltd. Genistein derivatives and anti-fungal composition containing the same
EP2074223A4 (en) * 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS
JP2008094751A (ja) * 2006-10-11 2008-04-24 Ono Pharmaceut Co Ltd プランルカスト水和物含有医薬組成物
CN102292097B (zh) 2008-12-11 2015-05-27 艾克赛特药品有限公司 染料木黄酮的晶型

Also Published As

Publication number Publication date
US20150290166A1 (en) 2015-10-15
US20120035253A1 (en) 2012-02-09
CN102292097B (zh) 2015-05-27
IL235943A0 (en) 2015-01-29
ZA201105045B (en) 2012-10-31
CA2746652A1 (en) 2010-06-17
JP6067781B2 (ja) 2017-01-25
IL213473A0 (en) 2011-07-31
US9012495B2 (en) 2015-04-21
KR101849059B1 (ko) 2018-04-13
JP2017061566A (ja) 2017-03-30
JP2015193630A (ja) 2015-11-05
JP2012512164A (ja) 2012-05-31
BRPI0923504A2 (pt) 2020-05-26
CN102292097A (zh) 2011-12-21
CN104860913A (zh) 2015-08-26
WO2010068861A1 (en) 2010-06-17
AU2009324489A1 (en) 2011-07-28
CN104860913B (zh) 2018-05-04
KR20110106355A (ko) 2011-09-28
EP2373326A4 (en) 2012-09-05
JP5898958B2 (ja) 2016-04-06
CA2746652C (en) 2018-03-06
AU2009324489B2 (en) 2015-11-12
EP2373326B1 (en) 2016-03-09
EP2373326A1 (en) 2011-10-12
KR20170091177A (ko) 2017-08-08
US9492425B2 (en) 2016-11-15
HK1164698A1 (en) 2012-09-28

Similar Documents

Publication Publication Date Title
IL213473A (en) Crystalline forms of genistein sodium salt dihydrate, compositions comprising the same and uses thereof
JP2024517496A (ja) Ｒｏｃｋ阻害剤の酸付加塩及び塩の結晶形、組成物並びに薬物用途
US7863325B2 (en) Crystalline genistein sodium salt dihydrate
ES2423821T3 (es) 5-(3,4-dicloro-fenil)-N-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma como agentes para aumentar el colesterol HDL
PT2788354T (pt) Funcionalização de ligandos de amina em gaiola para metalo-radiofármacos
JP2022543924A (ja) Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール化合物の塩形、結晶形及びその製造方法
WO2022171117A1 (zh) 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途
TW202313604A (zh) 吡唑並雜芳基類衍生物的可藥用鹽及其結晶形式
IL309711A (en) THIAZOLE-LACTAM-SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES
KR20230074839A (ko) 고체 형태의 ttk 억제제
CN114573459A (zh) β-榄香烯双胺基取代衍生物及其制备方法和应用
CN113999211A (zh) 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物
WO2022022569A1 (zh) 含氮杂环化合物的固体形式及其药物组合物和用途
HK1164698B (en) Crystalline forms of genistein
IL295992A (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(3,1-dimethyl-h1-pyrazol-4-yl)-h3-imidazo[5,4 -b]pyridine
PT1272490E (pt) Novo sal de um derivado azo do ácido 5-aminossalicílico
JP2025527820A (ja) キノリン誘導体阻害剤の結晶形、及びその調製方法並びに用途
TW202328138A (zh) 稠合二環類衍生物的可藥用鹽、晶型及其製備方法
CN121108109A (zh) 一种靶向alk蛋白的protac化合物及其抗肿瘤应用
TW202214645A (zh) 含氮雜環化合物的鹽及其鹽的固體形式、藥物組合物和用途
PL236095B1 (pl) Triazolo-chinolinowe pochodne alkaloidów drzewa chinowego, sposób ich otrzymywania oraz ich zastosowanie

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees